BACKGROUND: We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS: We conducted a nested-case-control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was >or=12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7-year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate-adjusted odds ratio (OR) for BPH risk. RESULTS: IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95% CI = 0.40-0.90 for the fifth vs. first quintile of IGFBP3, P-trend = 0.01). Associations did not differ by age (<65 or >or=65 years), and there was a suggestion that the IGFI:IGFBP3 - BPH risk association may be stronger among overweight men. CONCLUSIONS: A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS: We conducted a nested-case-control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was >or=12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7-year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate-adjusted odds ratio (OR) for BPH risk. RESULTS:IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95% CI = 0.40-0.90 for the fifth vs. first quintile of IGFBP3, P-trend = 0.01). Associations did not differ by age (<65 or >or=65 years), and there was a suggestion that the IGFI:IGFBP3 - BPH risk association may be stronger among overweight men. CONCLUSIONS: A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies. (c) 2008 Wiley-Liss, Inc.
Authors: Anand P Chokkalingam; Yu-Tang Gao; Jie Deng; Frank Z Stanczyk; Isabell A Sesterhenn; F K Mostofi; Joseph F Fraumeni; Ann W Hsing Journal: Prostate Date: 2002-07-01 Impact factor: 4.104
Authors: A Colao; S Spiezia; C Di Somma; P Marzullo; G Cerbone; R Pivonello; A Faggiano; G Lombardi Journal: Eur J Endocrinol Date: 2000-07 Impact factor: 6.664
Authors: P Stattin; A Bylund; S Rinaldi; C Biessy; H Déchaud; U H Stenman; L Egevad; E Riboli; G Hallmans; R Kaaks Journal: J Natl Cancer Inst Date: 2000-12-06 Impact factor: 13.506
Authors: J Ma; E Giovannucci; M Pollak; J M Chan; J M Gaziano; W Willett; M J Stampfer Journal: J Natl Cancer Inst Date: 2001-09-05 Impact factor: 13.506
Authors: A Colao; P Marzullo; S Spiezia; A Giaccio; D Ferone; G Cerbone; A Di Sarno; G Lombardi Journal: J Clin Endocrinol Metab Date: 2000-10 Impact factor: 5.958
Authors: Jocelyn S Kasper; Yan Liu; Michael N Pollak; Nader Rifai; Edward Giovannucci Journal: Cancer Causes Control Date: 2008-03-14 Impact factor: 2.506
Authors: Jeannette M Schenk; Alan R Kristal; Marian L Neuhouser; Catherine M Tangen; Emily White; Daniel W Lin; Mario Kratz; Ian M Thompson Journal: Am J Epidemiol Date: 2010-02-08 Impact factor: 4.897
Authors: Vaqar Mustafa Adhami; Imtiaz Ahmad Siddiqui; Sami Sarfaraz; Sabih Islam Khwaja; Bilal Bin Hafeez; Nihal Ahmad; Hasan Mukhtar Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531